Key Decisions Approved

1. Unaudited Financial Results: The Board approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2026, along with the Limited Review Report thereon in terms of provisions of Regulation 33 of SEBI Listing Regulations.

2. Director Appointment: The Board approved the appointment of Dr. Reeta Shah (DIN: 07141304) as an Additional Director (Non-Executive Independent Director) of the Company, for the first term of 5 consecutive years with effect from December 01, 2026, subject to approval of the shareholders.

Financial Performance Highlights (Standalone)

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from operations: ₹2,884.02 lakh (vs. ₹2,304.18 lakh in Q2 FY26)
  • Other income: ₹112.47 lakh (vs. ₹209.05 lakh in Q2 FY26)
  • Total Income: ₹2,895.26 lakh (vs. ₹2,325.09 lakh in Q2 FY26)
  • Total Expenses: ₹2,580.34 lakh (vs. ₹2,119.80 lakh in Q2 FY26)
  • Profit Before Tax: ₹314.93 lakh (vs. ₹205.29 lakh in Q2 FY26)
  • Tax Expense: ₹80.04 lakh (vs. ₹55.92 lakh in Q2 FY26)
  • Net Profit: ₹234.89 lakh (vs. ₹149.37 lakh in Q2 FY26)
  • Basic EPS: ₹2.34 (vs. ₹1.49 in Q2 FY26)

Half Year Ended September 30, 2026 (H1 FY27):

  • Revenue from operations: ₹5,492.20 lakh (vs. ₹4,573.30 lakh in H1 FY26)
  • Other income: ₹158.22 lakh (vs. ₹298.47 lakh in H1 FY26)
  • Total Income: ₹5,508.02 lakh (vs. ₹4,603.14 lakh in H1 FY26)
  • Total Expenses: ₹4,891.47 lakh (vs. ₹4,235.09 lakh in H1 FY26)
  • Profit Before Tax: ₹616.55 lakh (vs. ₹368.06 lakh in H1 FY26)
  • Tax Expense: ₹157.05 lakh (vs. ₹97.95 lakh in H1 FY26)
  • Net Profit: ₹459.49 lakh (vs. ₹270.10 lakh in H1 FY26)
  • Basic EPS: ₹4.58 (vs. ₹2.69 in H1 FY26)

Financial Performance Highlights (Consolidated)

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from operations: ₹2,882.73 lakh (vs. ₹2,370.55 lakh in Q2 FY26)
  • Other income: ₹112.47 lakh (vs. ₹211.55 lakh in Q2 FY26)
  • Total Income: ₹2,893.98 lakh (vs. ₹2,391.70 lakh in Q2 FY26)
  • Total Expenses: ₹2,579.50 lakh (vs. ₹2,165.66 lakh in Q2 FY26)
  • Profit Before Tax: ₹314.47 lakh (vs. ₹226.04 lakh in Q2 FY26)
  • Tax Expense: ₹79.79 lakh (vs. ₹57.82 lakh in Q2 FY26)
  • Net Profit: ₹234.69 lakh (vs. ₹168.24 lakh in Q2 FY26)
  • Basic EPS: ₹2.34 (vs. ₹1.68 in Q2 FY26)

Half Year Ended September 30, 2026 (H1 FY27):

  • Revenue from operations: ₹5,490.91 lakh (vs. ₹4,607.77 lakh in H1 FY26)
  • Other income: ₹158.22 lakh (vs. ₹304.07 lakh in H1 FY26)
  • Total Income: ₹5,506.73 lakh (vs. ₹4,638.18 lakh in H1 FY26)
  • Total Expenses: ₹4,891.86 lakh (vs. ₹4,239.40 lakh in H1 FY26)
  • Profit Before Tax: ₹614.87 lakh (vs. ₹398.78 lakh in H1 FY26)
  • Tax Expense: ₹157.05 lakh (vs. ₹99.85 lakh in H1 FY26)
  • Net Profit: ₹457.82 lakh (vs. ₹298.93 lakh in H1 FY26)
  • Basic EPS: ₹4.57 (vs. ₹2.98 in H1 FY26)

Balance Sheet Position (Standalone as of September 30, 2026)

  • Total Assets: ₹14,504.85 lakh (vs. ₹13,415.88 lakh as of March 31, 2026)
  • Non-Current Assets: ₹5,685.62 lakh
  • Current Assets: ₹8,819.23 lakh
  • Total Equity: ₹7,091.29 lakh (vs. ₹6,641.83 lakh as of March 31, 2026)
  • Non-Current Liabilities: ₹1,478.02 lakh
  • Current Liabilities: ₹5,935.54 lakh

Cash Flow Statement (Standalone H1 FY27)

  • Cash from Operating Activities: ₹53.37 lakh
  • Cash used in Investing Activities: ₹(428.10) lakh
  • Cash from Financing Activities: ₹406.88 lakh
  • Net increase in cash: ₹32.16 lakh
  • Cash and cash equivalents at end: ₹635.41 lakh

Director Appointment Details

  • Name: Dr. Reeta Shah (DIN: 07141304)
  • Position: Additional Director (Non-Executive Independent Director)
  • Effective Date: December 01, 2026
  • Term: First term of 5 consecutive years, subject to shareholder approval
  • Profile: Chartered Accountant with Ph.D. in Finance from IIT Bombay, LL.B., and three Master's degrees. Over 38 years of experience in Finance, Education and Administration. Previously served as Independent Director at Shemaroo Entertainment Limited for 10 years.
  • Relationship: Not related to any Director of the Company
  • Confirmation: Not debarred from holding office of Director by SEBI or any other authority

Audit and Compliance

  • The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2026
  • Statutory Auditors (Mittal Agarwal & Company) carried out limited review of the results
  • The company's business activity falls within a single operating segment: Pharmaceuticals
  • Previous year/quarter figures have been regrouped/reclassified where necessary

Meeting Details

  • The Board meeting commenced at 5:00 p.m. and concluded at 6:35 p.m. on November 14, 2026